Copart CEO Jeffrey Liaw Sells 27,745 Shares for $846,000

Copart CEO Jeffrey Liaw sold 27,745 shares at a weighted average $30.49 (about $846,000 total), reducing his direct stake by 22% to 99,641 shares; the trade followed a Rule 10b5-1 plan adopted April 15, 2025. The sale price was slightly below the $30.69 close on July 28, 2026, while the stock has fallen 33.4% over the prior 12 months. Despite slowing revenue growth (TTM revenue +1% YoY) EPS rose nearly 6% to $1.61, with a forward P/E of 17.7x and analysts expecting modest growth.

Analysis

The filing is mechanically noise: a 10b5-1 sale at this size does not change the fundamental story or even meaningfully alter insider alignment given the remaining common and derivative exposure. The real market signal is that investors are already paying for a much slower-growth business, so the stock is trading more like a durable fee compounder than a cyclical growth name; that makes the next leg of multiple expansion dependent on reacceleration, not just margin resilience.

The key second-order issue is that any sustained slowdown in auction volume or take-rate growth can pressure the ecosystem before it shows up in headline revenue: insurance carriers have more leverage on routing, fee negotiations, and inventory timing, while smaller remarketing platforms can try to compete on local service rather than network effects. If salvage values normalize or total-loss frequency stays soft, CPRT can still grow EPS, but the market may keep compressing the multiple because the “automatic compounding” narrative weakens.

Contrarian take: the selloff may already price most of the deceleration, so the downside from this filing alone looks limited unless the next two earnings prints confirm further low-single-digit growth. What would break the thesis is any evidence of volume reacceleration, a step-up in same-unit economics, or management guiding back to durable mid-single-digit top-line growth; absent that, the stock can remain a low-volatility value trap rather than a premium growth compounder.

Key Decisions for Investors

• Do not short CPRT on the insider sale alone; treat this as a watch item and wait for the next earnings/guidance update. The filing is non-catalytic, so an immediate trade is low edge.
• If CPRT trades below ~$29 ahead of earnings without a revision to estimates, consider initiating a starter long for a 12-18 month hold. Risk/reward improves because the market is already pricing a mature multiple, while FCF remains robust.
• Use CPRT vs. a weaker auto-services / salvage peer pair if you want relative value exposure: long CPRT, short KAR or RBA on any rally into earnings. The thesis is quality and network effects vs. more cyclical execution risk.
• Set a downside alert on a break below ~$28 with further revenue guidance cuts; that would indicate the market is right to re-rate CPRT toward a lower-quality fee business multiple.
• If next quarter shows volume stabilization or better-than-expected take rates, consider upside call spreads rather than outright stock. The catalyst is operating leverage on a stable fee base, not a rapid growth rebound.